Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other Non-Current Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 3.61% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 3.61% year-over-year, with the annual reading at $7.2 million for FY2025, 3.61% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $7.2 million at Lexicon Pharmaceuticals, down from $7.5 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $7.5 million in Q3 2025, with the low at $5.2 million in Q2 2025.
  • Average Other Non-Current Liabilities over 3 years is $6.1 million, with a median of $5.7 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities soared 31.51% in 2024, then fell 13.35% in 2025.
  • Over 3 years, Other Non-Current Liabilities stood at $5.3 million in 2023, then soared by 31.51% to $6.9 million in 2024, then grew by 3.61% to $7.2 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $7.2 million, $7.5 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.